文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Comparison of isatuximab-pomalidomide-dexamethasone elotuzumab-pomalidomide-dexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data.

作者信息

Martino Enrica Antonia, Pitino Annalisa, Offidani Massimo, Pepa Roberta Della, Gozzetti Alessandro, Bongarzoni Velia, Maroccia Antonio, Amico Valeria, Stefanoni Paola, Zamagni Elena, Terlizzi Sofia, Derudas Daniele, Palmieri Salvatore, Bianco Rosario, Conticello Concetta, Brunori Marino, Rago Angela, Lotti Flavia, Fontana Raffaele, Sgherza Nicola, Rossi Elena, Cafro Anna Maria, Febbo Massimiliano Arangio, Quinto Angela Maria, Cerchione Claudio, Casaluci Gloria Margiotta, Citro Annalisa, Califano Catello, Zambello Renato, Mangiacavalli Silvia, Liberatore Carmine, Buda Gabriele, De Magistris Claudio, Amendola Angela, Vigna Ernesto, Bruzzese Antonella, Barbieri Emiliano, Quaresima Micol, Roccotelli Daniela, Farina Francesca, Micozzi Jacopo, Vincelli Iolanda Donatella, Tarantini Giuseppe, Antonioli Elisabetta, Aquino Sara, Maggi Alessandro, Lombardo Alessandra, Bertuglia Giuseppe, Furlan Anna, Mele Anna, Annibali Ombretta, Cotzia Emilia, Benvenuti Pietro, De Paoli Lorenzo, Barilà Gregorio, Morè Sonia, De Stefano Valerio, Di Raimondo Francesco, Petrucci Maria Teresa, Bolli Niccolò, Musto Pellegrino, Neri Antonino, Morabito Fortunato, Tripepi Giovanni, Gentile Massimo

机构信息

Department of Onco-hematology, Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza.

Institute of Clinical Physiology (IFC-CNR), Rome.

出版信息

Haematologica. 2025 Mar 6;110(8):1875-1881. doi: 10.3324/haematol.2025.287325.

DOI:10.3324/haematol.2025.287325
PMID:40761134
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12358792/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bde2/12358792/1cf4086dcf32/1101875.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bde2/12358792/1cf4086dcf32/1101875.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bde2/12358792/1cf4086dcf32/1101875.fig1.jpg

相似文献

[1]
Comparison of isatuximab-pomalidomide-dexamethasone elotuzumab-pomalidomide-dexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data.

Haematologica. 2025-3-6

[2]
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.

Lancet. 2019-11-14

[3]
Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis.

Leuk Res. 2021-5

[4]
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study.

Lancet Oncol. 2022-3

[5]
Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics.

Br J Haematol. 2021-7

[6]
Comparative Efficacy of Ciltacabtagene Autoleucel Versus Standard-of-Care Treatments for Patients with Previously Treated Relapsed or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Comparison.

Adv Ther. 2025-5-12

[7]
Isatuximab: A Review of Its Use in Multiple Myeloma.

Target Oncol. 2021-9

[8]
EMA Review of Isatuximab in Combination with Pomalidomide and Dexamethasone for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma.

Oncologist. 2021-11

[9]
Continuous Elotuzumab, Pomalidomide, and Dexamethasone Maintenance Following Second Autologous Transplantation for Multiple Myeloma: Results of a Prospective Phase 2 Multicenter Trial.

Transplant Cell Ther. 2023-12

[10]
Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.

Blood Adv. 2025-3-11

引用本文的文献

[1]
Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma.

Cancers (Basel). 2025-3-30

本文引用的文献

[1]
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study.

Hematol Oncol. 2025-3

[2]
Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients.

ESMO Open. 2025-2

[3]
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials.

Haematologica. 2025-4-1

[4]
Clinical trial emulation in nephrology.

J Nephrol. 2025-1

[5]
Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma.

Blood Cancer J. 2024-7-19

[6]
Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management.

Am J Hematol. 2024-9

[7]
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials.

Hematol Oncol. 2024-7

[8]
Isatuximab-pomalidomide-dexamethasone pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis.

Haematologica. 2024-7-1

[9]
Teclistamab-cqyv in multiple myeloma.

Eur J Haematol. 2024-3

[10]
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials.

Haematologica. 2024-1-1

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索